Delivery Order SPE2DB20D1100-SPE2DB25FD7C0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,366.24 to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials. The contract, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, utilizes firm fixed price pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $10,024.40, is for the supply of 4,568,093,049 units of Remicade 100 mg vials. The award has no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a total ceiling value of $23,954.18 and covers the delivery of Remicade 100 mg vials. It is a firm fixed-price contract with an ultimate completion date of April 16, 2025. The contract is not set aside and represents an open competition. AmerisourceBergen Drug Corp holds a larger Indefinite...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,973.67 firm fixed-price delivery order is for the supply of REMICADE 100 MG VIALS, a specialty medication. The contract has an ultimate completion date of November 5, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- This is a delivery order worth $12,739.86 awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp under an Indefinite Delivery Contract (IDC) for the supply of 100mg vials of the biologic drug Remicade. The ultimate completion date for this delivery order is September 19, 2024. AmerisourceBergen, a major pharmaceutical distributor, is providing these critical medical supplies to support military treatment facilities and federal healthcare programs. The contract does not have...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $41,679.13, is for the delivery of Remicade 100 mg vials to support federal healthcare programs. The contract is a Firm Fixed Price Delivery Order, with a completion date of January 3, 2024. It is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $6,772.56 firm-fixed-price delivery order is for 4,567,525,171 units of the drug Remicade 100 mg vials. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to...
- The Defense Logistics Agency Troop Support Medical awarded a $12,826 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 100 mg vials of Remicade. The place of performance is Amerisourcebergen's facility in Conshohocken, Pennsylvania. The order runs from June 29, 2023 through June 30, 2023. Remicade is a biologic medication used to treat certain autoimmune disorders. This delivery order was awarded under an indefinite-delivery/indefinite-quantity contract vehicle held by...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,532.32 firm fixed-price contract is for the delivery of Remicade 100 mg vials, a specialty medication. The contract has a performance period through February 15, 2023 and was awarded on February 14, 2023. This delivery order is placed against AmerisourceBergen's existing $999,999,999 Indefinite Delivery...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,887.20 firm fixed price delivery order is for the supply of 100 mg REMICADE vials. The contract has an ultimate completion date of August 7, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD7C0Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $28,603.96 on July 29, 2025, for the supply of Remicade 100 mg vials, with a completion date of July 30, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was awarded through open competition. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's federal contract portfolio demonstrates extensive experience fulfilling diverse pharmaceutical needs across multiple therapeutic domains through DLA's Medical Supply Chain. Remicade, an immunosuppressive monoclonal antibody used to treat autoimmune conditions, represents one of many specialty medications the company supplies to support military and federal healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.6k | 7/29/25 |